Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancer
Taro Shibuki(National Cancer Center Hospital East), Masafumi Ikeda(National Cancer Center Hospital East), Tadayoshi Hashimoto(Osaka University), Binbin Zheng-Lin(WinnMed), Mohamad Bassam Sonbol(WinnMed), Mitsuho Imai(National Cancer Center Hospital East), Celine Hoyek(Mayo Clinic Hospital), Madhuri Gottam, Hani Babiker(Mayo Clinic in Florida), Cody R. Eslinger(WinnMed), Yoshiaki Nakamura(National Cancer Center Hospital East), Chigusa Morizane, Yasuyuki Kawamoto(Hokkaido University Hospital), Ryne Ramaker(Duke Cancer Institute), Makoto Ueno(Kanagawa Prefectural Hospital Organization), Shinji Itoh(Kyushu University), Nguyễn Trần Tố Trân(Mayo Clinic in Arizona), Takao Fujisawa(National Cancer Center Hospital East), John H. Strickler(Duke Cancer Institute), Takayuki Yoshino(National Cancer Center Hospital East), Angelo Pirozzi(Mayo Clinic in Arizona), Tanios Bekaii-Saab(Mayo Clinic in Arizona), Oluseyi Abidoye(Mayo Clinic), Hideaki Bando(National Cancer Center Hospital East), Kanae Inoue(National Cancer Center Hospital East)
Cited by 0
Related Papers
Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
|The Journal of Clinical Endocrinology & Metabolism|2015|328
Circulating Tumor DNA Profiling of Advanced Biliary Tract Cancers
|JCO Precision Oncology|2019|86
Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer
|Gastric Cancer|2019|71
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
|European Journal of Cancer|2024|47